JAWORSKI, Arkadiusz, SZYSZKA, Michal, BRZOSTEK, Karolina, SOBIERAJ, Jakub, LEWICKA, Wiktoria, MISIĄG-MARMURA, Weronika, SZALIŃSKI, Konrad, SOCZOMSKA, Pola, STOPA, Małgorzata and SOŚNIAK, Izabella. Paradoxical Antidepressant Effects of Sleep Deprivation in Depression: Mechanisms, Clinical Effects, and Therapeutic Implications. Journal of Education, Health and Sport. 2025;83:61758. eISSN 2391-8306.
https://doi.org/10.12775/JEHS.2025.83.61758
https://apcz.umk.pl/JEHS/article/view/61758

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 31.05.2025. Revised: 30.06.2025. Accepted: 05.07.2025. Published: 08.07.2025.

Paradoxical Antidepressant Effects of Sleep Deprivation in Depression: Mechanisms, Clinical Effects, and Therapeutic Implications

Authors:
Arkadiusz Jaworski
Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland
arkadiusz.jaworski@wum.edu.pl
https://orcid.org/0000-0002-1913-9518
Michał Szyszka
Lower Silesian Center for Oncology, Pulmonology and Hematology, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland
michal.m.szyszka@gmail.com
https://orcid.org/0009-0002-5307-1753
Karolina Brzostek
Department of Clinical Dietetics, Medical University of Warsaw, Warsaw, Poland
karolina.brzostek@gmail.com
https://orcid.org/0009-0004-1481-1100
Jakub Sobieraj
Students' Psychiatry Association, Wroclaw Medical University, Wrocław, Poland
j.sobirtaj@gmail.com
https://orcid.org/0000-0001-6562-316X
Wiktoria Lewicka
Lower Silesian Center for Oncology, Pulmonology and Hematology, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland
lewickawiktoria@gmail.com
https://orcid.org/0000-0002-6459-419X

Weronika Misiąg-Marmura
5th Military Hospital with Polyclinic in Cracow, Wrocławska 1–3, 30-901 Kraków, Poland
osu215wera@gmail.com
https://orcid.org/0000-0001-8638-2350
Konrad Szaliński
Jan Mikulicz-Radecki University Clinical Hospital, Borowska 213, 50-556 Wrocław, Poland
konrad.szalinski.mail@gmail.com
https://orcid.org/0009-0000-2753-5353
Pola Soczomska
Students' Psychiatry Association, Wroclaw Medical University, Wrocław, Poland
psoczomska@gmail.com
https://orcid.org/0009-0000-5395-8544
Małgorzata Stopa
J. Gromkowski Regional Specialist Hospital in Wrocław, Koszarowa 5, 51-149 Wrocław, Poland
stopa98@gmail.com
https://orcid.org/0000-0002-3456-2891
Izabella Sośniak
Brothers Hospitallers Hospital in Kraków, Trynitarska 11, 31-061 Kraków, Poland
iza.sosniak@gmail.com
https://orcid.org/0009-0000-9438-6175

Abstract

Introduction and purpose:
Sleep deprivation (SD), paradoxically, has been shown to induce rapid antidepressant effects in patients with depressive disorders. This review explores the neurobiological underpinnings, clinical efficacy, and therapeutic strategies involving SD, aiming to clarify the mechanisms responsible for its mood-elevating effects and to assess its role in modern treatment of depression.

Description of the state of knowledge:
Clinical evidence consistently shows that a single night of total or partial SD can lead to a rapid reduction in depressive symptoms in approximately 40–60% of patients. However, these effects are short-lived, with relapse typically occurring after recovery sleep. Combination therapies, such as SD with phase advance and bright light exposure, have been developed to prolong therapeutic benefits. On the neurobiological level, SD appears to act through multiple pathways: resetting dysregulated circadian rhythms, enhancing monoaminergic neurotransmission (particularly serotonin and dopamine), upregulating brain-derived neurotrophic factor (BDNF), and inducing synaptic plasticity. Acute activation of the hypothalamic–pituitary–adrenal axis and transient increases in inflammatory markers have also been observed, suggesting a complex physiological adaptation that accompanies mood improvement. Additionally, glial mechanisms involving adenosine signaling may contribute to the antidepressant response.

Summary:
Sleep deprivation represents a unique, non-pharmacological intervention capable of rapidly alleviating depressive symptoms. Although transient on its own, its combination with chronotherapeutic or pharmacological strategies offers promising avenues for sustained therapeutic effect. Insights from SD research deepen our understanding of depression's neurobiology and support the development of fast-acting antidepressant treatments that target circadian and neuroplastic mechanisms.

Keywords:
Sleep Deprivation; Depressive Disorder; Circadian Rhythm; Serotonin; Dopamine; Brain-Derived Neurotrophic Factor

Introduction and purpose

Depressive disorders are frequently accompanied by disturbances of sleep and circadian rhythms. Patients with major depression often suffer from insomnia, early-morning awakening, or disrupted sleep continuity, and these sleep abnormalities correlate with more severe mood symptoms [1-3]. Counterintuitively, however, depriving a depressed patient of sleep for a night can lead to a dramatic improvement in mood by the next day. This paradoxical antidepressant effect of sleep deprivation (often termed "wake therapy") was first observed over 50 years ago [4] and remains one of the most rapid interventions known to reduce depressive symptoms. The mood lift from staying awake all night stands in stark contrast to the effects of sleep loss in healthy individuals, who typically experience fatigue, cognitive impairment, and worsened mood or irritability with sleep deprivation. In depressed patients, by contrast, a night of wakefulness can abruptly switch a patient from a severely depressed state to a significantly improved state by the following afternoon [5]. This striking clinical phenomenon – sometimes described as "paradoxical" because sleep is normally restorative, not therapeutic when lost – has important implications for understanding depression and developing novel treatments.

The purpose of this review is to provide a comprehensive, up-to-date overview of the antidepressant effects of sleep deprivation in depression. We will first summarize the clinical findings on total and partial sleep deprivation as therapeutic interventions, including their efficacy, time course of antidepressant effects, and limitations (notably the high relapse rate after recovery sleep). We then delve into the neurobiological mechanisms proposed to underlie these effects, examining evidence for involvement of circadian rhythm realignment, monoamine neurotransmitters (especially serotonin and dopamine), neurotrophic factors like BDNF and synaptic plasticity, the stress hormone (HPA) axis, and inflammatory/immune changes. Throughout, we highlight how these mechanistic insights inform the clinical use of sleep deprivation and related chronotherapeutic strategies (such as controlled light exposure and sleep phase shifts) to maximize therapeutic benefits. The overall aim is to elucidate how a physiological stressor like sleep deprivation can temporarily reverse depressive pathology, what this reveals about depression biology, and how it can be harnessed in treatment. By reviewing both the state of knowledge and current hypotheses, we hope to provide clarity on this intriguing antidepressant phenomenon and guide future research and clinical applications.

Description of the state of knowledge

Clinical antidepressant effects of total and partial sleep deprivation

Acute sleep deprivation (SD) is a uniquely rapid antidepressant intervention. Numerous studies have confirmed that staying awake for an extended period (typically around 36 hours of continuous wakefulness for total sleep deprivation, or selectively depriving the patient of the second half of the night for partial sleep deprivation) can induce a marked improvement in depressive symptoms by the next day [6,7]. On average, approximately 40–60% of patients with major depressive episodes show a clinically significant response to a single night of SD [4,6]. This response rate has been consistent across decades of research: for example, a 2004 study of unmedicated depressed inpatients found about 60% showed transient improvement after one night of SD [6], and a meta-analysis in 2017 covering 66 studies reported that roughly half of patients achieved at least 50% reduction in symptoms following SD [8]. Intriguingly, partial sleep deprivation (in which patients sleep only 3–4 hours, usually in the first part of the night, and remain awake the rest) appears to be nearly as effective as total sleep deprivation. Response rates of ~50% have been reported for both modalities (e.g. ~50.4% for total SD vs ~53.1% for partial SD in one large meta-analysis) [9], indicating that it is the loss of the latter part of the night's sleep (when REM density is highest and circadian factors come into play) that may be critical for the antidepressant effect. Indeed, late-night/early-morning partial sleep deprivation (waking the patient at ~1–2 AM and preventing further sleep) is often used in clinical settings because it is somewhat more tolerable and can be repeated intermittently. Regardless of method, a key feature of the SD antidepressant response is its speed: patients frequently report mood lift within hours, often by the following afternoon, dramatically faster than conventional antidepressants which require weeks [10]. In some cases, one sleepless night can even alleviate suicidal ideation by the next day [10], illustrating the potential utility of SD in psychiatric emergencies. Patients describe feeling unexpectedly "better," with reduced sadness, increased mental clarity, and sometimes even transient euphoria or "wired" energy [5]. Notably, these improvements occur without any immediate pharmacological change, underlining the profound impact that manipulations of the sleep–wake cycle can have on brain mood circuits.

Clinical observation also reveals that the antidepressant effect of SD is more likely in certain patients. Those with a characteristic diurnal mood variation, whose depression is worse in the early morning and lifts somewhat by evening, have long been noted to respond well to SD [10]. By staying awake through the early morning hours (when their mood would typically be at its lowest), these patients seemingly avoid the usual dawn trough of mood and maintain the

improvement that develops over the day [11,12]. Bipolar depression (depressive episodes in bipolar disorder) is another context where SD can be effective – often even more consistently than in unipolar depression [13]. In fact, the antidepressant response to SD was first systematically studied in bipolar patients in the 1970s and 80s, and it remains an important option for treating bipolar depressive episodes [14]. Clinicians must monitor such patients closely, however, because sleep deprivation can also precipitate manic symptoms in bipolar individuals. Case reports indicate that while a bipolar patient's depression may lift with SD, there is a risk of switching into hypomania or mania, presumably because sleep loss is a known trigger for mania [5]. Therefore, SD therapy in bipolar disorder is usually combined with mood stabilizers (e.g. lithium) to mitigate this risk [15]. By contrast, in patients without any mood disorder, sleep loss generally does *not* improve mood – if anything, healthy individuals become more irritable or emotionally reactive when sleep-deprived [16]. This underscores that the SD antidepressant effect is tied to the pathophysiology of depression; it is not simply a generic consequence of arousal or positive thinking from being awake.

The major limitation of therapeutic sleep deprivation is that its antidepressant effect is remarkably short-lived. In most responders, the depressive symptoms return after the patient obtains even a single night of recovery sleep. As many as 80% or more of patients relapse into depression by the following day after they finally sleep [7,17]. One meta-analysis of over 1,700 depressed patients found that 83% of those who improved with SD relapsed after one night's sleep [18]. In fact, sometimes even a brief nap or unintended "microsleep" can abolish the mood improvement. Researchers have documented cases in which patients maintained their antidepressant response through the day after SD, only to have a few seconds of dozing off cause a sudden resurgence of depression [19]. This fragility suggests that continuous wakefulness is required to sustain the antidepressant state – once normal sleep/wake neurobiology resumes, the brain often reverts to the depressive baseline. The transient nature of the SD response has been a central puzzle and has spurred efforts to find ways to "lock in" or extend the gains from sleep deprivation.

To address the relapse problem, various chronotherapeutic strategies have been developed. One straightforward approach is to perform repeated sleep deprivation sessions, for example, two or three non-consecutive nights in a week. Early studies found that many patients who relapsed after the first night could again be lifted by a second SD, but the pattern of remission and relapse would simply repeat unless further measures were taken [20]. Repeated SD alone is generally not practical beyond a few sessions, as chronic sleep loss leads to accumulating sleep pressure and cognitive side effects. Thus, combination treatments have become the preferred approach.

One of the most effective combinations is sleep deprivation followed by a phase advance of sleep and concomitant bright light therapy. In this protocol, sometimes called the "triple chronotherapy," the patient stays awake for one entire night (SD), then for the next few days their sleep schedule is advanced (e.g. they go to bed in the early evening and wake in the early morning, effectively shifting the circadian phase earlier), and each morning they are exposed to high-intensity bright light [21,22]. This regimen, pioneered by researchers such as Wirz-Justice and colleagues, has been shown to stabilize and prolong the antidepressant effects of the initial sleep deprivation [11]. The phase advance and morning light are believed to reinforce the circadian clock adjustment that the SD triggers, thus preventing the relapse that would normally occur after returning to a regular sleep schedule. Studies in drug-resistant depression have reported rapid and sustained improvement using this combined chronotherapy approach, with some patients maintaining remission for weeks when followed by daily light therapy and structured sleep schedules [21,23].

Another important strategy is combining SD with pharmacotherapy. Notably, concurrent use of standard antidepressant medications can reduce relapse rates. In clinical trials, depressed patients who underwent sleep deprivation while continuing an antidepressant showed a significantly lower relapse rate after recovery sleep (~59% relapsed) compared to patients who had SD without medication (~83% relapsed). Certain antidepressants may even synergize with SD. For example, early reports indicated that the beta-blocker and 5-HT_1A antagonist pindolol could prolong the mood benefit of SD, presumably by modulating serotonin receptors [14,24]. More robust evidence exists for lithium: lithium augmentation has been found to sustain the SD response especially in bipolar depression [15]. In one controlled study, bipolar depressed patients receiving lithium who underwent early-morning partial sleep deprivation (awake from 2 AM onward) maintained their antidepressant response over at least 30 days, whereas those not on lithium relapsed quickly [15]. Lithium's stabilizing effect on circadian rhythms (it lengthens the circadian period and is thought to enhance clock gene amplitude) may underlie its ability to "lock in" the gains from SD [11,24].

In practice, combination approaches yield the best results. For instance, one protocol might be: keep the patient awake for 36 hours (Day 1 into Day 2); on Day 2 evening, allow only a short 4-hour sleep; thereafter, institute daily morning bright light and gradually increase nightly sleep by 15–30 minutes each day. Concurrently, maintain the patient on an antidepressant or mood stabilizer. Using such methods, studies have achieved sustained remission in about 50% of patients who initially responded to SD – a dramatic improvement over the ~5–10% who sustain remission with SD alone. While these chronotherapeutic interventions require intensive

scheduling, they capitalize on the unique rapid effect of SD and then prevent the typical relapse by actively manipulating the patient's circadian and sleep pattern in the ensuing days. This area of research, often termed antidepressant chronotherapy, has reinvigorated interest in non-pharmacological treatments for depression. It also exemplifies a core principle: depression can be powerfully influenced by behavioral and environmental manipulations (sleep–wake timing, light exposure), highlighting the role of fundamental biological rhythms in mood regulation [25,26].

Neurobiological mechanisms of the antidepressant effect

The rapid yet temporary improvement of depression with sleep deprivation suggests that fundamental regulatory systems in the brain are being perturbed. Unlike typical antidepressants that gradually induce molecular changes (over weeks) to relieve depression, sleep deprivation acts acutely, likely through neurobiological pathways that can be turned on (and off) quickly. Extensive research has converged on several key mechanisms.

Depression has been strongly linked to circadian rhythm disturbances – abnormalities in the 24-hour cycles of hormone secretion, sleep–wake timing, body temperature, and mood [10]. Many depressed patients (approximately 20–30%) show *phase-shifted or blunted circadian rhythms*, such as flattened cortisol rhythms, delayed melatonin onset, or the classic symptom of mood being worst in the early morning (dawn) and relatively better by evening. Importantly, when depression remits, these rhythms often normalize. The fact that one night of sleep deprivation can rapidly improve mood points to the circadian system as a likely mediator. Indeed, a leading hypothesis is that therapeutic wakefulness operates as a sort of circadian "reset" for the depressed brain [11]. By staying awake across the usual sleep period, the patient's internal clock may be shifted or synchronized in a way that alleviates depressive symptoms. Research by Bunney et al. has suggested that sleep deprivation might restart or re-phase the molecular clock in critical brain regions [11]. According to this model, depressed patients have an improperly phased or dampened expression of core clock genes (such as *BMAL1*, *CLOCK* and the *PERIOD* genes) in the suprachiasmatic nucleus and other tissues [11], contributing to their abnormal circadian rhythms and mood regulation. Sleep deprivation, especially when combined with subsequent phase advance and light, can acutely restore more normal timing to these gene expression cycles. Supporting this, animal studies and human fibroblast models show that sleep loss or shifting sleep timing can influence clock gene RNA levels and oscillation phases [10]. A recent genome-wide study of patients undergoing SD found acute changes in expression of several clock-controlled genes (including *PER2, PER3*, *BMAL1* and *NR1D1*) in blood cells [10], consistent with a systemic circadian adjustment. Moreover, specific genetic variants in clock

genes have been linked to differential responses to sleep deprivation. For example, a length polymorphism in the *PER3* gene (which affects an individual's intrinsic circadian period and sleep homeostasis) was found to influence how robustly patients respond to SD - *PER3* long-repeat carriers tended to have better mood outcomes. These findings reinforce the notion that correcting circadian dysregulation is central to SD's antidepressant action.

Interestingly, the rapid relapse upon resumption of sleep may also be circadian in nature: after recovery sleep, the abnormal circadian machinery could reassert itself, "reactivating" the depressive rhythms. This is why preventing a normal immediate sleep (via phase advance or continuing wake therapy) can sustain the benefit – it stops the clock from slipping back. Some authors have gone so far as to propose that circadian rhythm disturbance is a core feature of depressive pathophysiology, and that chronotherapeutic interventions (like SD and light therapy) directly target this core, unlike medications that act more indirectly [7,8,11]. The dramatic efficacy of sleep deprivation plus phase advance in some patients lends credence to this idea. In summary, aligning the circadian system – essentially *shifting the brain's internal time* – appears to be a fundamental mechanism by which sleep deprivation lifts mood. This aligns with the clinical observation that patients who improve often report a normalization of their daily mood variation (no more morning trough) after SD. It also dovetails with the strong interaction between sleep and depression: insomnia is both a symptom and a precipitant of depression [1], and therapies that improve sleep timing (like CBT for insomnia or light therapy) can have antidepressant effects in their own right. Sleep deprivation is the most extreme manipulation of the sleep–wake cycle, essentially forcing an immediate circadian readjustment, which in turn can abruptly reset mood regulation in the brain.

Another key mechanism involves serotonergic neurotransmission. The monoamine hypothesis of depression has long focused on serotonin (5-HT) deficiency in synapses. Conventional antidepressants such as SSRIs work by gradually enhancing serotoninergic neurotransmission, often through downstream changes like desensitization of inhibitory autoreceptors over weeks of treatment [27]. Sleep deprivation appears to converge on a similar endpoint more rapidly. During normal sleep, serotonin neuron firing in the dorsal raphe nucleus slows down (especially during REM sleep, when 5-HT activity is minimal) [27]. Prolonged wakefulness, conversely, keeps the raphe neurons active for an extended period, increasing serotonin release during the usual sleeping hours. Electrophysiological studies confirm that serotonin neurons maintain higher firing rates during enforced wakefulness. This sustained activation could flood certain brain regions with serotonin, acutely compensating for the functional 5-HT deficit associated with depression [27]. Joëlle Adrien and others have argued that the antidepressant effect of SD

can be explained by this activation of the serotonin system, analogous to what happens with SSRIs but on a faster timescale [27]. In support of a serotonergic role, a landmark study by Benedetti et al. found that a common genetic polymorphism affecting the serotonin transporter (5-HTTLPR) influences the outcome of total sleep deprivation [14]. Patients with the "long" variant of 5-HTTLPR (associated with more efficient serotonin reuptake and better SSRI response) had a significantly higher rate of improvement with sleep deprivation than those with the "short" variant. The authors concluded that the influence of 5-HTTLPR on SD response mirrors its influence on pharmacologic antidepressant response, reinforcing the idea that serotonin signaling is a major mediator of SD's mood effects. Another piece of evidence is that adding serotonergic agents can potentiate SD: for instance, combining SD with the 5-HT_1A autoreceptor antagonist pindolol (which boosts serotonin release) yielded greater antidepressant effects. Conversely, if the serotonin system is artificially suppressed, the antidepressant effect of SD might be blunted – although ethically such experiments in humans are difficult. (In animal models, there are mixed results: one microdialysis study in rats surprisingly found extracellular serotonin levels in hippocampus and frontal cortex *declined* over 8 hours of sleep deprivation [28], suggesting complex feedback mechanisms. The net effect in humans, however, is likely an increase in serotonin transmission, considering the clinical and genetic evidence.) Thus, enhanced serotonergic neurotransmission – via prolonged firing and adaptive receptor changes – is a plausible mechanism for why patients feel better after staying awake all night. It ties in elegantly with the pharmacology of depression and may explain the overlap in which patients benefit from SSRIs and from SD (e.g. those with certain genotypes or insomnia-related depression).

Beyond serotonin, dopamine has emerged as a crucial player in sleep deprivation's antidepressant action. Dopamine is central to the brain's reward and motivation pathways, which are often blunted in depression (manifesting as anhedonia). Sleep deprivation induces a distinctive "stimulant" effect that can leave patients feeling not only less depressed but also somewhat euphoric or energetic ("tired but wired"). This observation led researchers to examine dopamine activity under sleep loss conditions. Recent studies using positron emission tomography and optogenetics in animals have shown that acute sleep deprivation causes a surge in dopamine release in brain regions implicated in mood and reward, such as the striatum (nucleus accumbens) and prefrontal cortex [5]. A groundbreaking 2023 study by Wu and colleagues demonstrated in mice that one night of sleep loss resulted in increased firing of dopamine neurons and higher dopamine levels in the medial prefrontal cortex, nucleus accumbens, and hypothalamus [5]. Behaviorally, these mice showed reduced "depressive-like"

behavior (e.g. they were more willing to escape an unpleasant situation, indicating less hopelessness) and exhibited signs of hyperactivity and increased reward-seeking. Crucially, when researchers experimentally blocked dopamine signaling in the prefrontal cortex, the antidepressant-like effects of sleep deprivation in the mice disappeared. This implies that dopamine release in frontal brain regions is necessary for the mood improvement seen with sleep loss. In human studies, functional MRI has similarly found that sleep deprivation amplifies reactivity in mesolimbic reward circuits, including heightened striatal (ventral striatum) responses to positive stimuli or rewards [29,30]. This heightened dopaminergic responsiveness may temporarily counteract the anhedonia of depression, making ordinary activities or positive cues feel more rewarding and motivating [29]. In essence, by boosting dopamine-driven reward pathways, sleep deprivation can briefly reverse the deficit in positive affect that characterizes depression. This dopaminergic hypothesis aligns with the observation that some SD responders report a mood lift that borders on hypomania, with increased goal-directed energy, talkativeness, and optimism – all signs of dopamine-fueled neural activity. It also resonates with parallels to psychostimulant drugs (like amphetamines), which increase synaptic dopamine and can acutely improve mood and alertness. Of course, unlike sustained stimulant use, one night of SD doesn't cause addiction or a pathological dopamine overload, but the analogy highlights a shared mechanism. Notably, molecular studies indicate that sleep deprivation and fast-acting antidepressants (like ketamine) both converge on enhancing dopamine signaling and related gene expression. For example, both SD and ketamine were found to increase expression of certain plasticity-related genes and downregulate inhibitors of the MAP kinase pathway in prefrontal neurons [10], changes that promote synaptic potentiation and are often downstream of dopamine and glutamate receptor activation. Thus, elevated dopamine neurotransmission and reward circuit engagement is a key component of how sleep deprivation rapidly improves mood.

Further important contributors are neuroplasticity and BDNF. A striking aspect of sleep deprivation's action is its ability to induce rapid changes in synaptic plasticity – essentially "rewiring" certain neural circuits in ways that resemble the effects of other rapid antidepressants like ketamine. One measure of neuroplasticity is the level of brain-derived neurotrophic factor (BDNF), a growth factor that supports synaptic formation and neural resilience. Low BDNF levels have been consistently found in depressed patients, and successful antidepressant treatments (from SSRIs to electroconvulsive therapy) tend to raise BDNF levels over time [31]. Notably, sleep deprivation can also elevate BDNF on a much shorter timescale. Gorgulu and Caliyurt (2009) showed that depressed patients who underwent a series of total sleep

deprivation sessions had significant increases in serum BDNF concentration coinciding with their mood improvements [31]. Patients treated with sleep deprivation plus an SSRI had a faster rise in BDNF and quicker drop in depression ratings than those on the SSRI alone [31]. By the end of one week (with three SD nights), BDNF levels in responders had approached levels seen in healthy controls, paralleling a marked reduction in their depressive symptoms. This rapid neurotrophic response suggests that sleep loss triggers molecular cascades promoting synaptic plasticity and neuronal connectivity. In healthy volunteers, even a single night of partial sleep deprivation has been found to acutely increase BDNF the next day [32], which is consistent with the idea that wakefulness stimulates certain stress and plasticity mechanisms. Beyond BDNF protein levels, there is evidence from animal research that sleep deprivation causes actual structural synaptic changes. In mice, for example, one study found that acute sleep loss led to an increased density of dendritic spines (postsynaptic connections) on neurons in the medial prefrontal cortex [5]. Moreover, the ability to induce new spine formation by glutamate (via an LTP-like mechanism) was enhanced after sleep deprivation. These changes indicate a burst of synaptic remodeling and strengthening in frontal cortical circuits during the period of extended wakefulness. Interestingly, when researchers in that study used an optical technique to selectively eliminate the newly formed spines in the prefrontal cortex, the antidepressant behavioral effect of sleep deprivation in the mice was lost.

This provides direct evidence that synaptic plasticity is causally linked to the antidepressant outcome. Essentially, sleep deprivation seems to push the depressed brain into a more plastic, change-permitting state – it "shakes up" rigid neural networks that may be perpetuating depressive thought and behavior patterns, allowing a temporary normalization of network dynamics. In analogy, ketamine's rapid antidepressant effect is also attributed to a pulse of synaptogenesis and BDNF release in prefrontal circuits. Sleep deprivation might be achieving a similar feat through naturalistic means (via altered neuromodulators and excitatory/inhibitory balance during prolonged wakefulness). Additionally, other neurotrophic and growth factors could be involved (e.g. some studies hint at vascular endothelial growth factor or VEGF changes with SD, though BDNF is the most studied). In sum, promoting neuroplasticity – reflected by increased BDNF and new synaptic growth – is a critical mechanism by which sleep deprivation reverses depressive neurobiology. This plasticity likely underpins the mood improvements, as a more plastic brain can escape pathological network states associated with depression. It also explains why the effect can be so rapid: unlike slow genomic changes required for conventional antidepressants, sleep deprivation taps into fast-acting plasticity pathways (BDNF release, spine formation) that can occur within hours.

Sleep and the hypothalamic–pituitary–adrenal (HPA) axis interact in complex ways. Depression is often characterized by HPA axis hyperactivity – many patients have elevated cortisol levels, flattened diurnal cortisol variation, and impaired negative feedback of cortisol (as evidenced by abnormal dexamethasone suppression tests) [6]. Interestingly, a night of sleep deprivation appears to acutely activate the HPA axis in depressed patients in a distinct manner. During the SD night, plasma cortisol tends to run higher than on a normal night. One clinical study that sampled depressed patients' blood every 30 minutes found that cortisol levels were significantly higher during the SD night compared to baseline sleep night. Then, during the following day (after SD), responders showed an elevated cortisol in the morning hours (whereas non-responders did not). By the next recovery night, cortisol secretion returned to the patient's typical pattern. These results demonstrate that sleep deprivation triggers a transient stimulatory effect on the HPA axis in depression. At first glance, this is counterintuitive because one might expect raising cortisol (a stress hormone) to worsen depression. However, some researchers hypothesize that the cortisol surge from SD might actually contribute to the antidepressant effect via feedback mechanisms. One idea is that the high cortisol during SD temporarily restores more normal circadian amplitude or *re-sensitizes* glucocorticoid receptors, thereby improving the impaired negative feedback in depression. When cortisol levels spike and then decline, it could signal the hypothalamus to dampen further CRH release, leading to a kind of "reset" of an overactive stress system. Consistent with this, the same study noted that the cortisol elevation was most pronounced in patients who improved in mood (and not in those who failed to respond). This suggests a correlation where the magnitude of the cortisol shift predicted clinical response. Another possibility is that cortisol interacts with neurotransmitter systems – for example, cortisol can acutely increase dopamine synthesis and release or alter 5-HT receptor sensitivity – thus facilitating some of the monoamine changes described above. It is also conceivable that cortisol's metabolic and arousal effects help overcome the depressive inertia. Importantly, though, this "boost" is short-term: by the time the patient has recovery sleep, cortisol rhythms normalize and any beneficial effect is lost, paralleling the relapse of depression. This timeline fits the idea that the short-term HPA axis response is part of the mechanism, whereas long-term HPA overactivity is deleterious. In essence, sleep deprivation may acutely mobilize the body's stress response in a way that, for a brief window, actually has antidepressant consequences (perhaps by jolting dysfunctional systems into a different equilibrium). This aligns with the broader concept of "hormetic" effects – a little physiological stress can sometimes produce a favorable adaptive response. It also dovetails with the known link between HPA normalization and depression recovery: successful antidepressant treatments

tend to gradually normalize cortisol levels and feedback sensitivity over weeks. Sleep deprivation compresses some of that dynamic into hours (albeit not sustainably). Clinically, these findings caution that SD is physiologically taxing – the cortisol and sympathetic nervous system activation mean it's not a benign intervention, which is why repeated or chronic sleep loss is harmful. But understanding the HPA involvement provides a more integrated picture of the mind-body interplay during SD. It shows that SD doesn't simply act on the brain in isolation; it triggers a whole-body response (endocrine, autonomic, immune) that is entwined with the brain's mood circuits. Researchers continue to explore if manipulating the HPA axis could extend SD's effects – for instance, using corticosteroid receptor agonists or antagonists around the time of SD, though no clear application has emerged yet [6].

The next major contributor is inflammation and immune modulation. Depression has an inflammatory component in many patients (the so-called "cytokine hypothesis" of depression). Elevated pro-inflammatory cytokines like interleukin-6 (IL-6), TNF-α, and C-reactive protein (CRP) are found in a subset of people with depression and are thought to contribute to depressive symptoms such as fatigue, anhedonia, and anxiety. Acute sleep deprivation has a well-documented impact on immune markers. In general, sleep loss induces a pro-inflammatory state – even one night of partial sleep deprivation can raise daytime levels of IL-6 and TNF-α in otherwise healthy individuals [33,34]. Studies have shown that nocturnal cytokine concentrations (e.g. IL-6) increase during sleep deprivation nights, and this mirrors the elevated IL-6 observed in depressed patients [34,35]. On the surface, this seems counterproductive: if inflammation exacerbates depression, why would an effective antidepressant intervention acutely *increase* inflammatory signals? One possible interpretation is that the immune activation is a byproduct of the stress of sleep loss, not the cause of mood improvement, and might actually limit the duration of the antidepressant effect. In other words, while the circadian and neurotransmitter changes push mood upward, the mounting inflammatory response may gradually push it back down, contributing to relapse once sleep is resumed and the acute neurochemical "high" wears off. This might explain why the antidepressant effect cannot be maintained indefinitely – the body's immune system and stress reactions eventually counter-regulate. Some researchers have speculated that patients with high baseline inflammation might respond differently to sleep deprivation. There is evidence that depressed individuals with elevated inflammatory markers tend to have more persistent sleep problems and a blunted response to standard treatments [35,36]. It would be insightful to see if such patients respond less robustly to SD or relapse faster, but data are limited. One small study suggested that higher baseline IL-6 was associated with non-response to SD, possibly because the inflammatory state

interfered with the necessary neurobiological changes [35]. Conversely, it might be that SD works better in patients without a heavy inflammatory burden. These considerations are still speculative. What is clear is that sleep deprivation reliably triggers immune activation, including increased circulating monocytes producing pro-inflammatory cytokines [34,37]. It also transiently suppresses some aspects of cellular immunity (like NK cell activity) as part of the stress response. From a mechanistic perspective, some inflammation might actually signal the brain to induce neuroplastic changes (since inflammatory pathways can cross-talk with growth factor pathways in the brain). For instance, mild activation of TNF-α has been shown to promote sleep pressure and possibly synaptic strengthening in certain contexts – a "two-edged sword" effect where inflammation has both detrimental and adaptive roles. That said, the net role of inflammation in SD's antidepressant effect remains unclear. It could be more of a side-effect than a mechanism. Clinically, it reminds us that sleep deprivation is not a risk-free procedure, especially for those with medical conditions; the transient rise in inflammatory and stress markers could pose risks (e.g. for cardiovascular patients). Some researchers are looking at anti-inflammatory agents (like NSAIDs or cytokine inhibitors) given during SD to see if they extend the mood benefit or mitigate relapse, but results are not yet conclusive.

A fascinating line of research has shifted focus from neurons to glial cells, particularly astrocytes, in mediating the effects of sleep deprivation. Astrocytes are integral to sleep regulation – they control extracellular levels of adenosine, a neuromodulator that accumulates during prolonged wakefulness and induces sleep pressure. During sleep deprivation, astrocytes release more adenosine, which binds to A1 adenosine receptors on neurons and typically inhibits excitatory neurotransmission, contributing to the sleepiness feeling. One might expect this to simply induce sleep, but it turns out adenosine A1 receptor signaling might also have an antidepressant role. Hines et al. (2013) demonstrated in mice that the antidepressant-like behavioral effects of 12-hour sleep deprivation required astrocyte-derived adenosine acting on A1 receptors [38]. Mice genetically engineered to block gliotransmission (release of transmitters from astrocytes) did not show the usual reduction in depressive-like behavior after SD. Furthermore, simply activating A1 receptors pharmacologically (with an agonist) mimicked the antidepressant effect of sleep deprivation in those animals. These findings point to an intriguing mechanism: adenosine acting on A1 receptors is necessary and sufficient for the antidepressant response in that model. Normally, adenosine via A1 receptors promotes slow-wave sleep and inhibits arousal; however, in the depressed-brain context, that same signal might interrupt pathological activity patterns (for example, by inhibiting hyperactive neurons in circuits of rumination or stress). It is as if the brain, when sleep-deprived, uses the astrocyte–adenosine

system to enforce a calming, anti-depressant effect at the network level, even as it drives the person towards eventual sleep. This is a rapidly developing area, and more work is needed to translate it to human depression. Indirect support in humans comes from observations that caffeine (an adenosine receptor antagonist) can negate some cognitive effects of sleep deprivation, and one might wonder if caffeine would also block mood improvements – some case reports suggest patients should avoid caffeine during SD therapy to maximize benefit, possibly because it interferes with adenosine's action. It is also notable that lithium – which prolongs SD's effect – has interactions with adenosine signaling (lithium can increase adenosine tone by inhibiting its reuptake). This provides a potential molecular clue as to why lithium helps: it might amplify the astrocytic adenosine mechanism that maintains the antidepressant state [24].

In summary, the neurobiological mechanisms underlying sleep deprivation's antidepressant effects are multifaceted and interconnected. Circadian realignment, monoamine surge (serotonin, dopamine), neurotrophic and synaptic plasticity enhancement, stress-hormone modulation, immune activation, and glial signaling all appear to contribute to varying degrees. We can conceptualize that sleep deprivation temporarily "reboots" the depressed brain: it acutely shifts the timing of internal clocks, releases a flood of neurotransmitters, and induces a cascade of molecular changes that together push the brain out of a depressive state – but only as long as the unusual condition of sustained wakefulness is maintained. Once normal sleep resumes, homeostatic forces return the system to its prior depressive equilibrium (unless additional interventions keep it on the new track). This paints depression as at least partly a disorder of dysregulated rhythms and inadequate neuroplastic adaptation, which can be momentarily corrected by a drastic intervention like sleep loss. Such insights are driving new therapeutic ideas, from chronobiology-based treatments to fast-acting antidepressant drugs that target the same pathways (for example, drugs that boost dopamine or simulate aspects of sleep deprivation's neurochemical profile). Sleep deprivation research has thereby not only provided an emergency tool for managing depression, but also a valuable window into the biological underpinnings of mood.

Summary

The paradoxical antidepressant effects of sleep deprivation in depression illustrate the profound influence of the sleep–wake cycle on mood regulation. One night of total or partial sleep deprivation can produce a rapid and robust improvement in depressive symptoms in roughly half of patients with major depression. This unique intervention reliably demonstrates that

depressive states are not immutable – they can be abruptly reversed by modulating fundamental brain–body rhythms. The clinical utility of sleep deprivation lies in its speed; it offers almost immediate relief (within 12–48 hours), which is invaluable in severe cases such as suicidal depression. However, its limitations – notably the transient nature of the response and near-inevitable relapse after resuming sleep – mean that sleep deprivation is not a stand-alone long-term treatment. Instead, it serves as a potent initial "kick-start" to be followed by other therapies. Combining sleep deprivation with sleep phase advancement, bright light therapy, and pharmacotherapy has shown success in transforming the short-lived gains into more enduring remission. These combination approaches underscore that depression can be effectively treated by holistic chronotherapeutic strategies that tackle the dysregulated biological rhythms and sleep patterns inherent in the illness.

On the neurobiological level, sleep deprivation's antidepressant effect appears to result from a convergence of multiple mechanism: a resetting of aberrant circadian clocks, a surge of monoaminergic transmission (serotonin and dopamine release) that acutely improves mood and motivation, a promotion of synaptic plasticity and neurotrophic factor expression (e.g. BDNF) that helps remold neural networks, and modulatory effects on stress and immune pathways (transiently boosting cortisol and inflammatory markers) that may interact with brain signaling. The evidence suggests that depression involves a complex interplay of circadian, neurotransmitter, and synaptic abnormalities – and that sleep deprivation temporarily normalizes this interplay in a significant subset of patients. The fact that such relief can be attained without any medication, by simply altering sleep, highlights how central sleep and circadian processes are to mood disorders. It also validates the exploration of novel treatments targeting these processes. For instance, drugs that mimic aspects of sleep deprivation (such as enhancing dopamine or blocking certain serotonin receptors to replicate autoreceptor desensitization) or devices that stimulate similar brain network changes are being investigated as rapid antidepressants. Furthermore, the role of astrocytic adenosine signaling discovered in animal models opens up potential avenues for glia-targeted therapies.

In conclusion, the paradox of sleep deprivation in depression – that losing sleep can lift mood – has taught psychiatry several important lessons. First, it provides proof-of-concept that rapid reversal of depression is biologically possible, shattering the old notion that antidepressant effects must take weeks. This has in part paved the way for acceptance of other rapid treatments like ketamine. Second, it emphasizes the primacy of circadian and sleep mechanisms in affective illness; fixing the timing of sleep or the light exposure can be as efficacious as medications for some patients. Third, it has driven home the idea that depression is a systems-

level disorder of brain-body integration (involving sleep, neuroendocrine, immune, and neurotransmitter systems), and effective interventions can likewise be system-level (behavioral or environmental) modifications, not just receptor-specific drugs. Finally, the clinical use of sleep deprivation (in controlled settings) offers a rapid rescue therapy and can serve as a predictor of treatment response – patients who benefit from SD may respond well to certain antidepressants or chronotherapy, whereas non-responders might need different approaches. While not a cure on its own, therapeutic sleep deprivation remains a valuable tool in the psychiatric armamentarium and a fascinating example of how altering one of our most basic physiological drives – sleep – can so strikingly alter the state of mind. Continued research into this phenomenon is likely to yield deeper insights into depression and new approaches to achieve sustained remission by harnessing the mechanisms that sleep deprivation transiently engages.

Disclosure:

Author Contributions: Conceptualization, AJ, MSz, KB; methodology, AJ, MSz, WL, KB, WM-M, KS, PS, MS, IS, JS; formal analysis, AJ, MSz, KB; investigation, AJ, MSz, KB, WL, WM-M, JS, KS, PS, MS, IS; resources, AJ, MSz, PS; writing – original draft preparation, AJ, MSz, KB, WL, JS, WM-M, KS, PS, MS, IS; writing – review and editing, AJ, MSz, WL, KB, WM-M, KS, PS, MS, IS, JS; visualization, WL, KS, WM-M; supervision, AJ; project administration, AJ.

All authors have read and agreed with the published version of the manuscript.

Funding Statement: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflict of Interest Statement: All authors declare no conflict of interest.

Declaration of generative AI and AI-assisted technologies in the writing process: In preparing this work, the authors used *ChatGPT (OpenAI)* for the purpose of language editing and grammar correction only. After using this tool, the authors reviewed and edited the text as needed and accept full responsibility for the substantive content of the publication.

Acknowledgments: None.

References

1. Asarnow LD. Depression and sleep: what has the treatment research revealed and could the HPA axis be a potential mechanism? *Curr Opin Psychol*. Aug 2020;34:112-116. doi:10.1016/j.copsyc.2019.12.002

2. Sikora K, Łuczyk RJ, Wawryniuk A, Łuczyk M, Zwolak A. Anxiety and depression intensity and the quality of life of patients with an implanted pacemaker. *Journal of Education, Health and Sport*. 2021;11(6):170-177. doi:10.12775/jehs.2021.11.06.018

3. Egierska DM, Pietruszka P, Buchta J. The importance of sleep in selected diseases. *Journal of Education, Health and Sport*. 2021;11(8):334-341. doi:10.12775/jehs.2021.11.08.037

4. Pflug B, Tolle R. Disturbance of the 24-Hour Rhythm in Endogenous Depression and the Treatment of Endogenous Depression by Sleep Deprivation. *International Pharmacopsychiatry*. 2017;6(3):187-196. doi:10.1159/000468269

5. Wu M, Zhang X, Feng S, et al. Dopamine pathways mediating affective state transitions after sleep loss. *Neuron*. Jan 3 2024;112(1):141-154.e8. doi:10.1016/j.neuron.2023.10.002

6. Voderholzer U, Hohagen F, Klein T, et al. Impact of Sleep Deprivation and Subsequent Recovery Sleep on Cortisol in Unmedicated Depressed Patients. *American Journal of Psychiatry*. 2004;161(8):1404-1410. doi:10.1176/appi.ajp.161.8.1404

7. Hu B, Liu C, Mou T, et al. Meta-Analysis of Sleep Deprivation Effects on Patients With Depression. *Frontiers in Psychiatry*. 2021;12doi:10.3389/fpsyt.2021.783091

8. Boland EM, Rao H, Dinges DF, et al. Meta-Analysis of the Antidepressant Effects of Acute Sleep Deprivation. *J Clin Psychiatry*. Sep/Oct 2017;78(8):e1020-e1034. doi:10.4088/JCP.16r11332

9. Caliyurt O, Guducu F. Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder. *J Affect Disord*. Sep 2005;88(1):75-8. doi:10.1016/j.jad.2005.04.008

10. Sato S, Bunney B, Mendoza-Viveros L, et al. Rapid-acting antidepressants and the circadian clock. *Neuropsychopharmacology*. 2022;47(4):805-816. doi:10.1038/s41386-021-01241-w

11. Bunney BG, Bunney WE. Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. *Biol Psychiatry*. Jun 15 2013;73(12):1164-71. doi:10.1016/j.biopsych.2012.07.020

12. Reynolds CF, 3rd, Smith GS, Dew MA, et al. Accelerating symptom-reduction in late-life depression: a double-blind, randomized, placebo-controlled trial of sleep deprivation. *Am J Geriatr Psychiatry*. May 2005;13(5):353-8. doi:10.1176/appi.ajgp.13.5.353

13. NOBILE M, MARINO C, MOLTENI M, BATTAGLIA M. Some Ado About a Polymorphism. *American Journal of Psychiatry*. 2000;157(11):1886-a-1887. doi:10.1176/appi.ajp.157.11.1886-a

14. Benedetti F, Serretti A, Colombo C, et al. Influence of a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene on the Effects of Total Sleep Deprivation in Bipolar Depression. *American Journal of Psychiatry*. 1999;156(9):1450-1452. doi:10.1176/ajp.156.9.1450

15. Szuba MP, Baxter LR, Jr., Altshuler LL, et al. Lithium sustains the acute antidepressant effects of sleep deprivation: preliminary findings from a controlled study. *Psychiatry Res*. Mar 1994;51(3):283-95. doi:10.1016/0165-1781(94)90015-9

16. Giedke H, Schwärzler F. Therapeutic use of sleep deprivation in depression. *Sleep Medicine Reviews*. 2002/10/01/ 2002;6(5):361-377. doi:https://doi.org/10.1053/smrv.2002.0235

17. Lee H-J. Is Advancing Circadian Rhythm the Mechanism of Antidepressants? *Psychiatry Investigation*. 2019;16(7):479-483. doi:10.30773/pi.2019.06.20

18. Wu JCB, W. E. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. *American Journal of Psychiatry*. 1990;147(1):14-21. doi:10.1176/ajp.147.1.14

19. Kuhs H, Färber D, Borgstädt S, Mrosek S, Tölle R. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. *J Affect Disord*. Feb 12 1996;37(1):31-41. doi:10.1016/0165-0327(95)00074-7

20. Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, Hobi V. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment--neurobiological and psychometric assessment of course. *J Psychiatr Res*. Jul-Aug 1994;28(4):381-99. doi:10.1016/0022-3956(94)90020-5

21. Benedetti F, Dallaspezia S, Melloni EMT, et al. Effective Antidepressant Chronotherapeutics (Sleep Deprivation and Light Therapy) Normalize the IL-1β:IL-1ra Ratio in Bipolar Depression. *Frontiers in Physiology*. 2021;12doi:10.3389/fphys.2021.740686

22. Veale D, Serfaty M, Humpston C, et al. Out-patient triple chronotherapy for the rapid treatment and maintenance of response in depression: feasibility and pilot randomised controlled trial. *BJPsych Open*. 2021;7(6)doi:10.1192/bjo.2021.1044

23. Humpston C, Benedetti F, Serfaty M, et al. Chronotherapy for the rapid treatment of depression: A meta-analysis. *Journal of Affective Disorders*. 2020;261:91-102. doi:10.1016/j.jad.2019.09.078

24. Smeraldi E. Sustained Antidepressant Effect of Sleep Deprivation Combined with Pindolol in Bipolar Depression A Placebo-Controlled Trial. *Neuropsychopharmacology*. 1999;20(4):380-385. doi:10.1016/s0893-133x(98)00129-8

25. Elsenga S, van den Hoofdakker RH. Clinical effects of sleep deprivation and clomipramine in endogenous depression. *J Psychiatr Res*. 1982;17(4):361-74. doi:10.1016/0022-3956(82)90041-3

26. Smith GS, Reynolds CF, Houck PR, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: A randomized, placebo-controlled study. *Psychiatry Research: Neuroimaging*. 2009;171(1):1-9. doi:10.1016/j.pscychresns.2008.05.001

27. Adrien J. Neurobiological bases for the relation between sleep and depression. *Sleep Med Rev*. Oct 2002;6(5):341-51.

28. Bjorvatn B, Grønli J, Hamre F, et al. Effects of sleep deprivation on extracellular serotonin in hippocampus and frontal cortex of the rat. *Neuroscience*. 2002;113(2):323-30. doi:10.1016/s0306-4522(02)00181-1

29. Mullin BC, Phillips ML, Siegle GJ, Buysse DJ, Forbes EE, Franzen PL. Sleep deprivation amplifies striatal activation to monetary reward. *Psychological Medicine*. 2013;43(10):2215-2225. doi:10.1017/s0033291712002875

30. Gujar N, Yoo S-S, Hu P, Walker MP. Sleep Deprivation Amplifies Reactivity of Brain Reward Networks, Biasing the Appraisal of Positive Emotional Experiences. *The Journal of Neuroscience*. 2011;31(12):4466-4474. doi:10.1523/jneurosci.3220-10.2011

31. Gorgulu Y, Caliyurt O. Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. *Brain Res Bull*. Sep 28 2009;80(3):158-62. doi:10.1016/j.brainresbull.2009.06.016

32. Schmitt K, Holsboer-Trachsler E, Eckert A. BDNF in sleep, insomnia, and sleep deprivation. *Ann Med*. 2016;48(1-2):42-51. doi:10.3109/07853890.2015.1131327

33. Thompson KI, Chau M, Lorenzetti MS, Hill LD, Fins AI, Tartar JL. Acute sleep deprivation disrupts emotion, cognition, inflammation, and cortisol in young healthy adults. *Frontiers in Behavioral Neuroscience*. 2022;16doi:10.3389/fnbeh.2022.945661

34. Felger JC, Lotrich FE. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. *Neuroscience*. 2013;246:199-229. doi:10.1016/j.neuroscience.2013.04.060

35. Voderholzer U, Fiebich BL, Dersch R, et al. Effects of Sleep Deprivation on Nocturnal Cytokine Concentrations in Depressed Patients and Healthy Control Subjects. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 2012;24(3):354-366. doi:10.1176/appi.neuropsych.11060142

36. Hurtado-Alvarado G, Pavón L, Castillo-García SA, et al. Sleep Loss as a Factor to Induce Cellular and Molecular Inflammatory Variations. *Clinical and Developmental Immunology*. 2013;2013:1-14. doi:10.1155/2013/801341

37. Garbarino S, Lanteri P, Bragazzi NL, Magnavita N, Scoditti E. Role of sleep deprivation in immune-related disease risk and outcomes. *Communications Biology*. 2021;4(1)doi:10.1038/s42003-021-02825-4

38. Hines DJ, Schmitt LI, Hines RM, Moss SJ, Haydon PG. Antidepressant effects of sleep deprivation require astrocyte-dependent adenosine mediated signaling. *Translational Psychiatry*. 2013;3(1):e212-e212. doi:10.1038/tp.2012.136